Autumn Gaither-Davis - Search Results

Year	Number of Results
2004	1
2005	1
2007	1
2010	2
2012	1
2015	1
2016	1
2017	3
2018	1
2019	1
2020	1
2021	1
2024	1

1

ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.

Yoneyama T, Gorry M, Sobo-Vujanovic A, Lin Y, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, Stabile LP, Herman J, Vujanovic NL. Yoneyama T, et al. Among authors: gaither davis a. J Cancer. 2018 Jun 23;9(14):2559-2570. doi: 10.7150/jca.24601. eCollection 2018. J Cancer. 2018. PMID: 30026855 Free PMC article.

2

Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden.

Stabile LP, Kumar V, Gaither-Davis A, Huang EH, Vendetti FP, Devadassan P, Dacic S, Bao R, Steinman RA, Burns TF, Bakkenist CJ. Stabile LP, et al. Among authors: gaither davis a. JCI Insight. 2021 Feb 8;6(3):e145307. doi: 10.1172/jci.insight.145307. JCI Insight. 2021. PMID: 33351788 Free PMC article.

3

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.

Bauman JE, Ohr J, Gooding WE, Ferris RL, Duvvuri U, Kim S, Johnson JT, Soloff AC, Wallweber G, Winslow J, Gaither-Davis A, Grandis JR, Stabile LP. Bauman JE, et al. Among authors: gaither davis a. Cancers (Basel). 2020 Jun 11;12(6):1537. doi: 10.3390/cancers12061537. Cancers (Basel). 2020. PMID: 32545260 Free PMC article.

4

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Espinosa-Cotton M, Fertig EJ, Stabile LP, Gaither-Davis A, Bauman JE, Schmitz S, Gibson-Corley KN, Cheng Y, Jensen IJ, Badovinac VP, Laux D, Simons AL. Espinosa-Cotton M, et al. Among authors: gaither davis a. Biomark Res. 2019 Jul 16;7:14. doi: 10.1186/s40364-019-0164-0. eCollection 2019. Biomark Res. 2019. PMID: 31346466 Free PMC article.

5

KRAS and TP53 mutations in bronchoscopy samples from former lung cancer patients.

Gao W, Jin J, Yin J, Land S, Gaither-Davis A, Christie N, Luketich JD, Siegfried JM, Keohavong P. Gao W, et al. Among authors: gaither davis a. Mol Carcinog. 2017 Feb;56(2):381-388. doi: 10.1002/mc.22501. Epub 2016 Jun 6. Mol Carcinog. 2017. PMID: 27182622

6

TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer.

Kumar V, Yochum ZA, Devadassan P, Huang EH, Miller E, Baruwal R, Rumde PH, GaitherDavis AL, Stabile LP, Burns TF. Kumar V, et al. Oncogene. 2024 Mar 1. doi: 10.1038/s41388-024-02987-5. Online ahead of print. Oncogene. 2024. PMID: 38485737

7

15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers.

Leng S, Liu Y, Weissfeld JL, Thomas CL, Han Y, Picchi MA, Edlund CK, Willink RP, Gaither Davis AL, Do KC, Nukui T, Zhang X, Burki EA, Van Den Berg D, Romkes M, Gauderman WJ, Crowell RE, Tesfaigzi Y, Stidley CA, Amos CI, Siegfried JM, Gilliland FD, Belinsky SA. Leng S, et al. Among authors: gaither davis al. J Natl Cancer Inst. 2015 Feb 23;107(5):djv035. doi: 10.1093/jnci/djv035. J Natl Cancer Inst. 2015. PMID: 25713168 Free PMC article.

8

Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR.

Ostrow KL, Hoque MO, Loyo M, Brait M, Greenberg A, Siegfried JM, Grandis JR, Gaither Davis A, Bigbee WL, Rom W, Sidransky D. Ostrow KL, et al. Among authors: gaither davis a. Clin Cancer Res. 2010 Jul 1;16(13):3463-72. doi: 10.1158/1078-0432.CCR-09-3304. Epub 2010 Jun 30. Clin Cancer Res. 2010. PMID: 20592015 Free PMC article.

9

Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates.

Yoneyama T, Gorry M, Miller MA, Gaither-Davis A, Lin Y, Moss ML, Griffith LG, Lauffenburger DA, Stabile LP, Herman JG, Vujanovic NL. Yoneyama T, et al. Among authors: gaither davis a. J Cancer. 2017 Oct 23;8(19):3916-3932. doi: 10.7150/jca.20779. eCollection 2017. J Cancer. 2017. PMID: 29187866 Free PMC article.

10

Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.

Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM. Tarhini AA, et al. Among authors: gaither davis a. Cancer. 2017 Aug 1;123(15):2936-2944. doi: 10.1002/cncr.30717. Epub 2017 May 4. Cancer. 2017. PMID: 28472537 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

15 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year